Literature DB >> 21881840

Expression of matrix metalloproteinase-1, -9, -13, and tissue inhibitor of metalloproteinases-1 in basal cell carcinomas of the eyelid.

Zornitsa I Zlatarova1, Ekaterina B Softova, Klara G Dokova, Elisabeth M Messmer.   

Abstract

BACKGROUND: Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) function in the remodelling of the extracellular matrix in morphogenesis, angiogenesis, tissue repair, and tumor invasion. Elevated levels of distinct MMPs in tumor tissue are related to worse prognosis. However, no overall consistent pattern of expression in human cancer has been identified. The aim of the present study was to evaluate the expression of MMP-1, -9, -13 and TIMP-1 in tumor epithelial cells and surrounding connective tissue in primary basal cell carcinomas (BCC) of the eyelid, and to assess their role as prognostic markers for tumor recurrence.
METHODS: Surgical specimens of 49 histologically proven primary BBCs of the eyelid of different histological subtypes were included. Immunohistological studies were performed using antibodies against MMP-1, MMP-9, MMP-13 and TIMP-1, and staining intensity was analyzed semi-quantitatively.
RESULTS: MMP-1, -9, -13, and TIMP-1 were expressed at various intensities in epithelial tumor cells and surrounding stromal cells including fibroblasts, inflammatory cells, and vascular endothelial cells in all tumor subtypes. Staining was especially prominent at the invading edge of the BCC. A statistically significant correlation was seen between increased TIMP-1 expression in tumor and/or stromal cells with the presence of MMP-13 (p = 0.007 and p < 0.0001 respectively). Moreover, TIMP-1 expression in tumor and/or stroma was significantly associated with relapse (p = 0.012 and p = 0.042 respectively).
CONCLUSION: MMP-9, MMP-13 and TIMP-1 expression may serve as a prognostic marker for early tumor invasiveness. Moreover, up-regulation of TIMP-1 in tumor and/or surrounding stromal cells may indicate an increased risk for BCC recurrence.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21881840     DOI: 10.1007/s00417-011-1810-x

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  34 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

Review 2.  Proteases in invasion: matrix metalloproteinases.

Authors:  W G Stetler-Stevenson; A E Yu
Journal:  Semin Cancer Biol       Date:  2001-04       Impact factor: 15.707

3.  Do basal cell carcinomas recur after complete conventional surgical excision?

Authors:  R W Griffiths; S K Suvarna; J Stone
Journal:  Br J Plast Surg       Date:  2005-09

4.  Positive margins in basal cell carcinoma: relationship to clinical features and recurrence risk. A retrospective study of 248 patients.

Authors:  E Nagore; C Grau; J Molinero; J M Fortea
Journal:  J Eur Acad Dermatol Venereol       Date:  2003-03       Impact factor: 6.166

5.  Histologic pattern analysis of basal cell carcinoma. Study of a series of 1039 consecutive neoplasms.

Authors:  M Sexton; D B Jones; M E Maloney
Journal:  J Am Acad Dermatol       Date:  1990-12       Impact factor: 11.527

6.  Matrix metalloproteinases: biologic activity and clinical implications.

Authors:  A R Nelson; B Fingleton; M L Rothenberg; L M Matrisian
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

7.  Partial sequencing and characterization of the tumor cell-derived collagenase stimulatory factor.

Authors:  K Nabeshima; W S Lane; C Biswas
Journal:  Arch Biochem Biophys       Date:  1991-02-15       Impact factor: 4.013

8.  Matrix metalloproteinase-1 is the major collagenolytic enzyme responsible for collagen damage in UV-irradiated human skin.

Authors:  Meghan Brennan; Humaa Bhatti; Kamalakar C Nerusu; Narasimharao Bhagavathula; Sewon Kang; Gary J Fisher; James Varani; John J Voorhees
Journal:  Photochem Photobiol       Date:  2003-07       Impact factor: 3.421

9.  Immunolocalizations of human gelatinase (type IV collagenase, MMP-9) and TIMP (tissue inhibitor of metalloproteinases) in normal epidermis and some epidermal tumors.

Authors:  T Kobayashi; N Onoda; T Takagi; H Hori; S Hattori; Y Nagai; S Tajima; T Nishikawa
Journal:  Arch Dermatol Res       Date:  1996-05       Impact factor: 3.017

10.  Induction of matrix metalloproteinase-1 (MMP-1) during epidermal invasion of the stroma in human skin organ culture: keratinocyte stimulation of fibroblast MMP-1 production.

Authors:  S E Moon; M K Dame; D R Remick; J T Elder; J Varani
Journal:  Br J Cancer       Date:  2001-11-16       Impact factor: 7.640

View more
  4 in total

1.  Expression of metalloproteinases (MMP-2 and MMP-9) in basal-cell carcinoma.

Authors:  Anna Goździalska; Anna Wojas-Pelc; Jagoda Drąg; Paweł Brzewski; Jerzy Jaśkiewicz; Maciej Pastuszczak
Journal:  Mol Biol Rep       Date:  2016-07-12       Impact factor: 2.316

2.  Matrix metalloproteinase 13-containing exosomes promote nasopharyngeal carcinoma metastasis.

Authors:  Yiwen You; Ying Shan; Jing Chen; Huijun Yue; Bo You; Si Shi; Xingyu Li; Xiaolei Cao
Journal:  Cancer Sci       Date:  2015-10-13       Impact factor: 6.716

Review 3.  Matrix metalloproteinases in keratinocyte carcinomas.

Authors:  Pilvi Riihilä; Liisa Nissinen; Veli-Matti Kähäri
Journal:  Exp Dermatol       Date:  2020-09-17       Impact factor: 3.960

4.  The immunoexpression of MMP-1 and MMP-13 in eyelid basal cell carcinoma.

Authors:  Irina Maria Mercuţ; Cristiana Eugenia Simionescu; Alex Emilian Stepan; Bianca Cătălina Andreiana; Ana Maria Ciurea; Răzvan Mercuţ; Marius Eugen Ciurea
Journal:  Rom J Morphol Embryol       Date:  2020 Oct-Dec       Impact factor: 1.033

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.